Shire (LSE: SHP) and AstraZeneca (LSE: AZN) are two very different companies with very different outlooks. Shire is growing rapidly and snapping up smaller peers to complement organic growth, but the company's shares are relatively expensive.
That is exactly what has happened to AstraZeneca (LSE: AZN). It was a hugely successful business that posted impressive growth numbers but, since 2012, has seen its bottom line fall by 41% as it has lost the exclusivity on various blockbuster drugs.
Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) has signed a partnership deal with AstraZeneca plc (ADR) (NYSE:AZN), to exclusively develop and market the drug-maker's experimental psoriasis drug, brodalumab.
Neil Woodford is one of AstraZeneca (LSE: AZN) GlaxoSmithKline's (LSE: GSK) most vocal supporters. The star fund manager has sung the praises of Astra and Glaxo's management many times over, and he commended Astra's decision to turn down US ...
Who is the real competitor to AstraZeneca (LSE: AZN) and GlaxoSmithKline (LSE: GSK)? In an obvious way they're competing with each other and with the other major blockbuster drug researchers around the world.